Hibiskus

Kalamazoo, United States Founded: 2017 • Age: 9 yrs Acquired By Lodo Therapeutics
Small-molecule therapeutics for cancer are developed by Hibiskus.

About Hibiskus

Hibiskus is a Healthcare company based in Kalamazoo (United States) founded in 2017 by Andre Bachmann and Michael Pirrung, and was acquired by Lodo Therapeutics in September 2020. Small-molecule therapeutics for cancer are developed by Hibiskus. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Innate Immune System. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.

Company details

Hibiskus Biopharma is a developer of small-molecule therapeutic solutions for cancer treatment. It has developed TIR-199 drugs that work as a potent proteasome inhibitor from the syrbactin natural product family. The product contains a proteasome inhibitor that helps to induce cell death of tumor cell types. It inhibits the digestive function of proteasomes which induces a cytotoxic buildup of cellular proteins that activates apoptotic pathways. It has developed FDA-approved drugs, target multiple myeloma, antibodies that produce cells in the blood others. Features include high-potency against proteasome activity cellular proliferation indicating a superior safety profile, induces cell death, and others.

  • Headquarters Kalamazoo, United States
  • Founders Andre Bachmann, Michael Pirrung
  • Stage Acquired
  • Sectors
    Healthcare
  • Website hibiskusbio.com
  • Acquired by Lodo Therapeutics (Sep 2020)
Key Metrics

Investors in Hibiskus

Hibiskus has secured backing from 1 investor. Prominent investors backing the company include Lodo Therapeutics.

All
InvestorDescriptionFounded YearDomainLocation
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
2015lodotherapeutics.comNew York, United States
Premium access

Investor details for Hibiskus

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Hibiskus

2 people are tracked at Hibiskus (2 in leadership).

NameRoleGroup
Andre Bachmann
Co-FounderLeadership
Michael Pirrung
Co-FounderLeadership
Premium access

Complete people profiles for Hibiskus

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Hibiskus

2 dated milestones of Hibiskus across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Hibiskus is founded.
  2. Exit Acquired by Lodo Therapeutics.

Competitors of Hibiskus

Hibiskus has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
revmed.com2014Redwood, United States$326.29M181
Cancer therapies are developed using selective pathway inhibitors.
blueprintmedicines.com2008Cambridge, United States$115M201
Selective kinase inhibitors are developed for genomically defined cancers.
syndax.com2005Waltham, United States$198.29M107
Targeted therapies for cancer treatment are developed.
Premium access

Detailed competitors of Hibiskus

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Hibiskus (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Hibiskus

Premium access

Complete news archive for Hibiskus

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hibiskus

Hibiskus was founded in 2017.

Hibiskus is headquartered in Kalamazoo, United States. It is registered at Kalamazoo, Michigan, United States.

Hibiskus Biopharma is a developer of small-molecule therapeutic solutions for cancer treatment. It has developed TIR-199 drugs that work as a potent proteasome inhibitor from the syrbactin natural product family. The product contains a proteasome inhibitor that helps to induce cell death of tumor cell types. It inhibits the digestive function of proteasomes which induces a cytotoxic buildup of cellular proteins that activates apoptotic pathways. It has developed FDA-approved drugs, target multiple myeloma, antibodies that produce cells in the blood others. Features include high-potency against proteasome activity cellular proliferation indicating a superior safety profile, induces cell death, and others.

Hibiskus's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.

Hibiskus has 1 investor. Key investors include Lodo Therapeutics.

Yes. Hibiskus was acquired by Lodo Therapeutics in September 2020.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available